Stockreport

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis

Corvus Pharmaceuticals, Inc.  (CRVS) 
Last corvus pharmaceuticals, inc. earnings: 4/30 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: corvuspharma.com
PDF Atopic dermatitis is the first immune disease indication being studied in the clinic for soquelitinib, the Company’s selective ITK inhibitor Corvus anticipates releasin [Read more]